Genmab and AbbVie blood cancer drug combination confirmed to reduce risk of death

智通财经2026/10/06 07:01

Show original

Traders expect Genmab's stock price to rise by 5%-7% after the combination blood cancer drug developed in collaboration with AbbVie was proven to reduce mortality risk.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

U.S. Stock Market Movement: Cameco surged on October 6th due to Korea-U.S. framework, Westinghouse equity, and uranium fuel

Bitget异动解读•2026/10/06 15:40

US Stock Moves: Caris Life Sciences plummeted on October 6 due to a correction from highs and executive share reduction.

Bitget异动解读•2026/10/06 15:35

McDonald's franchisees express concerns about the cost and details of the NEXT program

McDonald's (MCD.US) franchisees have expressed concerns about the costs and details of the "NEXT" plan.

智通财经•2026/10/06 15:31

Disney’s lawyers claim the FCC is attempting to scrutinize ABC’s coverage of the Trump administration

During a court hearing, Disney (DIS.US) lawyers stated that the U.S. Federal Communications Commission "wants to block, review, and control" ABC's coverage of the Trump administration.

智通财经•2026/10/06 15:31